Health Economics›B-cell acute lymphoblastic leukemia›Relapsed or refractory

Relapsed or refractory

B-cell acute lymphoblastic leukemia · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Blinatumomab monotherapy Variant #05	BCR::ABL1	R 4 812 257	56d	—	7.7 mo	1	R 4 812 257 PFS proxy	1
Blinatumomab monotherapy Variant #05	—	R 4 812 257	56d	—	7.7 mo	1	R 4 812 257 PFS proxy	1
Cytarabine, Idarubicin, Rituximab Variant #01	—	R 81 748	—	—	—	~1	~R 81 748 indirect	—
FLAG Variant #01	—	R 47 479	—	—	6.7 mo	2	R 94 958 PFS proxy	1
Nilotinib monotherapy Variant #01	BCR::ABL1	R 28 002	28d	—	—	~2	~R 56 004 indirect	—
7+3m Variant #01	—	R 13 839	7d	—	6.7 mo	1	R 13 839 PFS proxy	1
Dasatinib monotherapy Variant #01	BCR::ABL1	R 12 899	28d	—	—	~2	~R 25 797 indirect	—
Cytarabine and Idarubicin Variant #01	—	R 12 853	30d	—	—	~1	~R 12 853 indirect	—
Augmented Hyper-CVAD/MA and Asparaginase Variant #01 Partial	—	R 11 848	35d	—	—	~4	~R 47 392 indirect	—
Hyper-CVAD/MA and Everolimus Variant #01	—	R 6 150	—	—	—	~8	~R 25 910 indirect	—
High-dose Cytarabine monotherapy (HiDAC) Variant #01	—	R 3 498	—	—	6.7 mo	1	R 3 498 PFS proxy	1
Imatinib monotherapy Variant #16	BCR::ABL1	R 1 401	28d	~20.0 mo	~53.0 mo	~2	~R 2 801 PFS proxy · indirect	8
Cytarabine monotherapy Variant #01	—	R 357	30d	—	—	~2	~R 713 indirect	—
Vincristine liposomal monotherapy Variant #01 Partial	—	—	7d	—	—	~2	—	—
Brexucabtagene autoleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Bosutinib monotherapy Variant #01 Partial	BCR::ABL1	—	28d	—	—	~2	—	—
Cytarabine and Mitoxantrone (MC) Partial	—	—	—	—	—	—	—	—
Ponatinib monotherapy Variant #01 Partial	BCR::ABL1	—	28d	—	—	~2	—	—
BCG vaccine monotherapy Variant #01 Partial	—	—	30d	—	~38.6 mo	~1	—	1
Pentostatin monotherapy Variant #01 Partial	—	—	14d	—	—	~1	—	—
TBI Variant #01	—	—	—	—	—	—	—	4
Clofarabine monotherapy Variant #01 Partial	—	—	42d	—	—	~12	—	1
Inotuzumab ozogamicin monotherapy Variant #01 Partial	—	—	28d	—	7.7 mo	5	—	1
Tisagenlecleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—

24 of 24 regimens shown